Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations

Lipids

Volumn 49, Issue 12, 2014, Pages 1245-1249

  Niesor, Eric J ^a   Kallend, David ^a,b   Bentley, Darren ^c   Kastelein, John J P ^d   Kees Hovingh, G ^d   Stroes, Erik S G ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Medicines Company   (Switzerland)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ABCA1; Cholesterol; Dalcetrapib; HDL; Phytosterol

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CAMPESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; ABCA1 PROTEIN, HUMAN; APOA1 PROTEIN, HUMAN; CETP PROTEIN, HUMAN; CHOLESTEROL; LATHOSTEROL; THIOL DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERLIPEMIA; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GENE MUTATION; HUMAN; LIPID BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; GENETICS; HYPOALPHALIPOPROTEINEMIAS; MUTATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

APOLIPOPROTEIN A-I; ATP BINDING CASSETTE TRANSPORTER 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYPOALPHALIPOPROTEINEMIAS; MUTATION; PHYTOSTEROLS; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84921938886     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-014-3956-x     Document Type: Article

References (25)

1. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD (2012) High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32:2813-2820
2. Kontush A (2014) HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 103:341-349
3. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR (2006) Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Investig 116:1052-1062
4. Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR (2006) Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res 99:672-674
5. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C (2010) Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 51:3443-3454
6. Maugeais C, Perez A, von der Mark E, Magg C, Pflieger P, Niesor EJ (2013) Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta 1831:1644-1650
7. Niesor EJ, Chaput E, Staempfli A, Blum D, Derks M, Kallend D (2011) Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis 219:761-767
8. Nunes VS, Leanca CC, Panzoldo NB, Parra E, Cazita PM, Nakandakare ER, de Faria EC, Quintao EC (2011) HDL-C concentration is related to markers of absorption and of cholesterol synthesis: study in subjects with low vs. high HDL-C. Clin Chim Acta 412:176-180
9. Sutherland WH, Robertson MC, Williamson SA, Nye ER (1991) Plasma noncholesterol sterols in male distance runners and sedentary men. Eur J Appl Physiol Occup Physiol 63:119-123
10. Leichtle AB, Helmschrodt C, Ceglarek U, Shai I, Henkin Y, Schwarzfuchs D, Golan R, Gepner Y, Stampfer MJ, Bluher M, Stumvoll M, Thiery J, Fiedler GM (2011) Effects of a 2-y dietary weight-loss intervention on cholesterol metabolism in moderately obese men. Am J Clin Nutr 94:1189-1195
11. Bisoendial RJ, Hovingh GK, El HK, Levels JH, Tsimikas S, Pu K, Zwinderman AE, Kuivenhoven JA, Kastelein JJ, Stroes ES (2005) Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25:e133-e134
12. National Institutes of Health (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. NIH, Bethesda
13. Harchaoui KE, Franssen R, Hovingh GK, Bisoendial RJ, Stellaard F, Kuipers F, Kastelein JJ, Kuivenhoven JA, Stroes ES, Groen AK (2009) Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis 207:614-616
14. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378:1547-1559
15. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA (2012) Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 163:515-521
16. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE (2012) Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 33:857-865
17. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099
18. Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, Anzures-Cabrera J, Lehnert V, Pauly-Evers M, Holme I, Stasek J, van Hessen MW, Jones P (2014) The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 35:1792-1800
19. Lupattelli G, Siepi D, De VS, Roscini AR, Crisanti F, Covelli D, Pirro M, Mannarino E (2012) Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sci 90:846-850
20. Yamaguchi S, Zhang B, Tomonaga T, Seino U, Kanagawa A, Segawa M, Nagasaka H, Suzuki A, Miida T, Yamada S, Sasaguri S, Doi T, Saku K, Okazaki M, Tochino Y, Hirano K-I (2014) Selective evaluation of high density lipoprotein from mouse small intestines by an in situ perfusion technique. J Lipid Res 55:905-918
21. Iqbal J, Parks JS, Hussain MM (2013) Lipid absorption defects in intestine-specific microsomal triglyceride transfer protein and ATP-binding cassette transporter A1-deficient mice. J Biol Chem 288:30432-30444
22. Robins SJ, Fasulo JM (1997) High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest 99:380-384
23. Gylling H, Hallikainen M, Kolehmainen M, Toppinen L, Pihlajamaki J, Mykkanen H, Agren JJ, Rauramaa R, Laakso M, Miettinen TA (2007) Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl Res 149:310-316
24. Simonen P, Gylling H, Howard AN, Miettinen TA (2000) Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 72:82-88
25. Kruit JK et al (2006) Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12:6429-6439